Concert Pharmaceuticals Inc (CNCE:NASDAQ) Investor Relations Material

Overview

Concert Pharmaceuticals is a biopharmaceutical company focused on developing small molecule drugs for a variety of medical conditions, including central nervous system disorders, genetic diseases, and inflammatory disease. The company's clinical-stage product candidates include AVP-786, CTP-499, and CTP-354, which are currently in various stages of clinical trials. AVP-786 is being studied as a treatment for neurologic and psychiatric disorders, while CTP-499 is being tested for chronic kidney disease in type 2 diabetes patients. CTP-354 is in its early stages of clinical trials for spasticity associated with spinal cord injury and multiple sclerosis.

Frequently Asked Questions

What is Concert Pharmaceuticals Inc's ticker?

Concert Pharmaceuticals Inc's ticker is CNCE

What exchange is Concert Pharmaceuticals Inc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Concert Pharmaceuticals Inc's headquarters?

They are based in Lexington, Massachusetts

How many employees does Concert Pharmaceuticals Inc have?

There are 51-200 employees working at Concert Pharmaceuticals Inc

What is Concert Pharmaceuticals Inc's website?

It is http://www.concertpharma.com/

What type of sector is Concert Pharmaceuticals Inc?

Concert Pharmaceuticals Inc is in the Healthcare sector

What type of industry is Concert Pharmaceuticals Inc?

Concert Pharmaceuticals Inc is in the Biotechnology industry

Who are Concert Pharmaceuticals Inc's peers and competitors?

The following five companies are Concert Pharmaceuticals Inc's industry peers:

- Phathom Pharmaceuticals

- ChromaDex

- InflaRx N.V.

- Myokardia Inc

- Aerpio Pharmaceuticals, Inc.